Ignite Creation Date:
2025-12-24 @ 3:58 PM
Ignite Modification Date:
2026-02-20 @ 11:34 AM
Study NCT ID:
NCT00439192
Status:
TERMINATED
Last Update Posted:
2007-08-08
First Post:
2007-02-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
Sponsor:
elbion AG
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ELB245201-06
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None